| Consensus Statement | Quality of Evidence | Strength of Rec. | Key Ref |
|---|---|---|---|
| 1. Fulvestrant in combination with a CDK 4/6 inhibitor may be offered to patients who experienced disease progression during prior treatment with endocrine therapy. | I | A | 1-5 |
| 2. Alpelisib plus fulvestrant or AI is a treatment option for patients with PIK3CA-mutanted breast cancer who have progressed on endocrine therapy with or without a CDK4/6 inhibitor. | I | A | 6-8 |
| 3. Everolimus plus any other endocrine therapy is an option for patients who have progressed on prior endocrine therapy. | I-II | B | 9-13 |
| 4. CDK4/6 inhibitor combined with switching endocrine therapy is a treatment option for HR+, HER2- advanced breast cancer after CDK4/6 progression with endocrine therapy. | II | B | 14-15 |
| 5. Capivasertib plus fulvestrant is a treatment choice for one or more PIK3CA/AKT1/PTEN alterations metastatic breast cancer after at least one line of endocrine therapy in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. | I | A | 16 |
References
- Cristofanilli M, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo… (PALOMA-3). Lancet Oncol 2016.
- Slamon DJ, et al. Phase III randomized study of ribociclib and fulvestrant… MONALEESA-3. J Clin Oncol. 2018.
- Slamon DJ, et al. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. N Engl J Med 2020.
- Sledge GW, Jr., et al. MONARCH 2: Abemaciclib in Combination With Fulvestrant… J Clin Oncol 2017.
- Sledge GW, Jr., et al. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival… MONARCH 2. JAMA Oncol 2020.
- Andre F, et al. Alpelisib for PIK3CA Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med 2019.
- André F, et al. Alpelisib plus fulvestrant for PIK3CA-mutated… SOLAR-1. Ann Oncol. 2021.
- Rugo H, et al. Alpelisib plus fulvestrant… (BYLieve). Lancet Oncol 2021.
- Baselga J, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012.
- Cook MM, et al. Everolimus plus exemestane treatment… Oncologist. 2021.
- Piccart M, et al. Everolimus plus exemestane… BOLERO-2. Ann Oncol. 2014.
- Kornblum N, et al. Randomized Phase II Trial of Fulvestrant Plus Everolimus… PrE0102. J Clin Oncol.
- Bachelot T, et al. Randomized Phase II Trial of Everolimus in Combination With Tamoxifen… GINECO Study. J Clin Oncol.
- Kalinsky K, et al. Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib… MAINTAIN Trial. J Clin Oncol. 2023.
- Kalinsky K, et al. Abemaciclib Plus Fulvestrant… postMONARCH Trial.
- Turner NC, et al. Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer. N Engl J Med. 2023.